Mr. Kim brings extensive biotechnology-focused finance experience to his role on NCAP’s Investment Committee.
‍

He was most recently the vice president of Finance at Dyne Therapeutics, a clinical-stage biotechnology firm focussed on delivering life-transforming therapies for people with muscular disorders.

‍

Previously, he served as vice president of finance at Kaleido Biosciences, where he led the build-out of the company’s financial planning and analysis capabilities. Prior to joining Kaleido, Mr. Kim served as senior director of FP&A at Versartis, where he was responsible for the company’s budgeting process, played a key role in the execution of the company’s Initial Public Offering and supported investor relations initiatives.

‍

Previously, he served in various roles within the finance organizations at Pharmacyclics, Onyx Pharmaceuticals and Gilead Sciences. Mr. Kim began his career in investment banking supporting the Global Healthcare division at Lehman Brothers.

‍

Mr. Kim earned a B.A. in electrical engineering from the University of California at Los Angeles.